This trial is studying the side effects and best dose of vorinostat when given with temozolomide to treat patients with malignant gliomas.
1 Primary · 2 Secondary · Reporting Duration: Up to 4 years
Experimental Treatment
83 Total Participants · 1 Treatment Group
Primary Treatment: Vorinostat · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: